Which has preferable earnings & valuation, HURA or RLMD?

Relmada Therapeutics is trading at a lower price-to-earnings ratio than TuHURA Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TuHURA Biosciences N/A N/A -$30.05M -$0.61 N/A Relmada Therapeutics N/A N/A -$57.38M -$1.09 N/A

Is HURA or RLMD more profitable?

Relmada Therapeutics' return on equity of -71.22% beat TuHURA Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets TuHURA Biosciences N/A -156.12% -105.38% Relmada Therapeutics N/A -71.22% -64.46%

Does the media prefer HURA or RLMD?

In the previous week, Relmada Therapeutics had 4 more articles in the media than TuHURA Biosciences. MarketBeat recorded 6 mentions for Relmada Therapeutics and 2 mentions for TuHURA Biosciences. Relmada Therapeutics' average media sentiment score of 1.29 beat TuHURA Biosciences' score of 0.80 indicating that Relmada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TuHURA Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Relmada Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PRME or HURA?

In the previous week, Prime Medicine had 2 more articles in the media than TuHURA Biosciences. MarketBeat recorded 4 mentions for Prime Medicine and 2 mentions for TuHURA Biosciences. TuHURA Biosciences' average media sentiment score of 0.80 beat Prime Medicine's score of 0.69 indicating that TuHURA Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TuHURA Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is HURA or NGNE more profitable?

Neurogene's return on equity of -37.88% beat TuHURA Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets TuHURA Biosciences N/A -156.12% -105.38% Neurogene N/A -37.88% -34.70%

Does the media prefer HURA or NGNE?

In the previous week, TuHURA Biosciences and TuHURA Biosciences both had 2 articles in the media. TuHURA Biosciences' average media sentiment score of 0.80 beat Neurogene's score of 0.58 indicating that TuHURA Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TuHURA Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neurogene 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ARVN or HURA more profitable?

TuHURA Biosciences has a net margin of 0.00% compared to Arvinas' net margin of -247.54%. Arvinas' return on equity of -44.38% beat TuHURA Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Arvinas -247.54% -44.38% -28.38% TuHURA Biosciences N/A -156.12% -105.38%

Does the media favor ARVN or HURA?

In the previous week, Arvinas had 10 more articles in the media than TuHURA Biosciences. MarketBeat recorded 12 mentions for Arvinas and 2 mentions for TuHURA Biosciences. TuHURA Biosciences' average media sentiment score of 0.80 beat Arvinas' score of 0.56 indicating that TuHURA Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arvinas 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive TuHURA Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to HURA or SLN?

In the previous week, TuHURA Biosciences and TuHURA Biosciences both had 2 articles in the media. Silence Therapeutics' average media sentiment score of 1.00 beat TuHURA Biosciences' score of 0.80 indicating that Silence Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TuHURA Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Silence Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

TuHURA Biosciences (HURA) Competitors

$2.12 -0.02 (-0.70%)

As of 02:34 PM Eastern

Compare

HURA vs. RLMD, PRME, NGNE, ARVN, and SLN

Should you buy TuHURA Biosciences stock or one of its competitors? MarketBeat compares TuHURA Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with TuHURA Biosciences include Relmada Therapeutics (RLMD), Prime Medicine (PRME), Neurogene (NGNE), Arvinas (ARVN), and Silence Therapeutics (SLN).

How does TuHURA Biosciences compare to Relmada Therapeutics?

TuHURA Biosciences (NASDAQ:HURA) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

TuHURA Biosciences has a beta of -0.01, indicating that its share price is 101% less volatile than the broader market. Comparatively, Relmada Therapeutics has a beta of 0.46, indicating that its share price is 54% less volatile than the broader market.

In the previous week, Relmada Therapeutics had 4 more articles in the media than TuHURA Biosciences. MarketBeat recorded 6 mentions for Relmada Therapeutics and 2 mentions for TuHURA Biosciences. Relmada Therapeutics' average media sentiment score of 1.29 beat TuHURA Biosciences' score of 0.80 indicating that Relmada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TuHURA Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Relmada Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Relmada Therapeutics is trading at a lower price-to-earnings ratio than TuHURA Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.61	N/A
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A

TuHURA Biosciences currently has a consensus target price of $9.00, indicating a potential upside of 323.53%. Relmada Therapeutics has a consensus target price of $12.00, indicating a potential upside of 119.58%. Given TuHURA Biosciences' higher possible upside, research analysts clearly believe TuHURA Biosciences is more favorable than Relmada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

0.6% of TuHURA Biosciences shares are owned by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are owned by institutional investors. 6.1% of TuHURA Biosciences shares are owned by company insiders. Comparatively, 14.5% of Relmada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Relmada Therapeutics' return on equity of -71.22% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TuHURA Biosciences	N/A	-156.12%	-105.38%
Relmada Therapeutics	N/A	-71.22%	-64.46%

Summary

Relmada Therapeutics beats TuHURA Biosciences on 9 of the 13 factors compared between the two stocks.

How does TuHURA Biosciences compare to Prime Medicine?

Prime Medicine (NASDAQ:PRME) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.

70.4% of Prime Medicine shares are held by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are held by institutional investors. 16.0% of Prime Medicine shares are held by company insiders. Comparatively, 6.1% of TuHURA Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Prime Medicine had 2 more articles in the media than TuHURA Biosciences. MarketBeat recorded 4 mentions for Prime Medicine and 2 mentions for TuHURA Biosciences. TuHURA Biosciences' average media sentiment score of 0.80 beat Prime Medicine's score of 0.69 indicating that TuHURA Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prime Medicine	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TuHURA Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TuHURA Biosciences has lower revenue, but higher earnings than Prime Medicine. TuHURA Biosciences is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.03M	130.52	-$201.14M	-$1.23	N/A
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.61	N/A

Prime Medicine currently has a consensus price target of $7.53, indicating a potential upside of 158.36%. TuHURA Biosciences has a consensus price target of $9.00, indicating a potential upside of 323.53%. Given TuHURA Biosciences' higher possible upside, analysts plainly believe TuHURA Biosciences is more favorable than Prime Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

TuHURA Biosciences has a net margin of 0.00% compared to Prime Medicine's net margin of -4,917.55%. TuHURA Biosciences' return on equity of -156.12% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	-4,917.55%	-188.82%	-60.97%
TuHURA Biosciences	N/A	-156.12%	-105.38%

Prime Medicine has a beta of 2.26, indicating that its stock price is 126% more volatile than the broader market. Comparatively, TuHURA Biosciences has a beta of -0.01, indicating that its stock price is 101% less volatile than the broader market.

Summary

Prime Medicine beats TuHURA Biosciences on 10 of the 16 factors compared between the two stocks.

How does TuHURA Biosciences compare to Neurogene?

TuHURA Biosciences (NASDAQ:HURA) and Neurogene (NASDAQ:NGNE) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, media sentiment, institutional ownership, profitability and dividends.

0.6% of TuHURA Biosciences shares are held by institutional investors. Comparatively, 52.4% of Neurogene shares are held by institutional investors. 6.1% of TuHURA Biosciences shares are held by company insiders. Comparatively, 11.7% of Neurogene shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Neurogene's return on equity of -37.88% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TuHURA Biosciences	N/A	-156.12%	-105.38%
Neurogene	N/A	-37.88%	-34.70%

TuHURA Biosciences has higher earnings, but lower revenue than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than TuHURA Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.61	N/A
Neurogene	$930K	582.97	-$90.35M	-$4.55	N/A

TuHURA Biosciences has a beta of -0.01, meaning that its stock price is 101% less volatile than the broader market. Comparatively, Neurogene has a beta of 1.7, meaning that its stock price is 70% more volatile than the broader market.

In the previous week, TuHURA Biosciences and TuHURA Biosciences both had 2 articles in the media. TuHURA Biosciences' average media sentiment score of 0.80 beat Neurogene's score of 0.58 indicating that TuHURA Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TuHURA Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neurogene	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TuHURA Biosciences presently has a consensus price target of $9.00, suggesting a potential upside of 323.53%. Neurogene has a consensus price target of $84.83, suggesting a potential upside of 147.23%. Given TuHURA Biosciences' higher possible upside, equities analysts clearly believe TuHURA Biosciences is more favorable than Neurogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Neurogene	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Neurogene beats TuHURA Biosciences on 8 of the 14 factors compared between the two stocks.

How does TuHURA Biosciences compare to Arvinas?

Arvinas (NASDAQ:ARVN) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

In the previous week, Arvinas had 10 more articles in the media than TuHURA Biosciences. MarketBeat recorded 12 mentions for Arvinas and 2 mentions for TuHURA Biosciences. TuHURA Biosciences' average media sentiment score of 0.80 beat Arvinas' score of 0.56 indicating that TuHURA Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arvinas	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
TuHURA Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arvinas has a beta of 1.71, meaning that its stock price is 71% more volatile than the broader market. Comparatively, TuHURA Biosciences has a beta of -0.01, meaning that its stock price is 101% less volatile than the broader market.

TuHURA Biosciences has a net margin of 0.00% compared to Arvinas' net margin of -247.54%. Arvinas' return on equity of -44.38% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arvinas	-247.54%	-44.38%	-28.38%
TuHURA Biosciences	N/A	-156.12%	-105.38%

TuHURA Biosciences has lower revenue, but higher earnings than Arvinas. TuHURA Biosciences is trading at a lower price-to-earnings ratio than Arvinas, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arvinas	$262.60M	2.18	-$80.80M	-$3.32	N/A
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.61	N/A

95.2% of Arvinas shares are held by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are held by institutional investors. 7.3% of Arvinas shares are held by insiders. Comparatively, 6.1% of TuHURA Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Arvinas presently has a consensus target price of $15.42, suggesting a potential upside of 73.57%. TuHURA Biosciences has a consensus target price of $9.00, suggesting a potential upside of 323.53%. Given TuHURA Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe TuHURA Biosciences is more favorable than Arvinas.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arvinas	2 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.38
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Arvinas beats TuHURA Biosciences on 9 of the 15 factors compared between the two stocks.

How does TuHURA Biosciences compare to Silence Therapeutics?

TuHURA Biosciences (NASDAQ:HURA) and Silence Therapeutics (NASDAQ:SLN) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, media sentiment, risk, dividends, profitability and institutional ownership.

0.6% of TuHURA Biosciences shares are held by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are held by institutional investors. 6.1% of TuHURA Biosciences shares are held by insiders. Comparatively, 3.0% of Silence Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

TuHURA Biosciences currently has a consensus price target of $9.00, indicating a potential upside of 323.53%. Silence Therapeutics has a consensus price target of $55.00, indicating a potential upside of 389.54%. Given Silence Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Silence Therapeutics is more favorable than TuHURA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

TuHURA Biosciences has a beta of -0.01, suggesting that its share price is 101% less volatile than the broader market. Comparatively, Silence Therapeutics has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market.

TuHURA Biosciences has higher earnings, but lower revenue than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than TuHURA Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.61	N/A
Silence Therapeutics	$560K	947.75	-$88.61M	-$1.59	N/A

TuHURA Biosciences has a net margin of 0.00% compared to Silence Therapeutics' net margin of -8,943.86%. Silence Therapeutics' return on equity of -105.34% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TuHURA Biosciences	N/A	-156.12%	-105.38%
Silence Therapeutics	-8,943.86%	-105.34%	-52.79%

In the previous week, TuHURA Biosciences and TuHURA Biosciences both had 2 articles in the media. Silence Therapeutics' average media sentiment score of 1.00 beat TuHURA Biosciences' score of 0.80 indicating that Silence Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TuHURA Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Silence Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Silence Therapeutics beats TuHURA Biosciences on 9 of the 15 factors compared between the two stocks.

Get TuHURA Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HURA vs. The Competition

Export

Metric	TuHURA Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$135.32M	$3.54B	$6.80B	$13.01B
Dividend Yield	N/A	3.79%	2.60%	10.03%
P/E Ratio	-3.48	7.36	279.98	25.51
Price / Sales	N/A	1,272.68	649.35	116.02
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	6.25	17.18	11.15	6.35
Net Income	-$30.05M	-$12.52M	$3.48B	$347.60M
7 Day Performance	-0.23%	2.48%	2.51%	3.14%
1 Month Performance	-12.91%	-5.41%	-2.78%	-2.08%
1 Year Performance	-17.95%	51.14%	64.32%	21.27%

TuHURA Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HURA TuHURA Biosciences	1.8704 of 5 stars	$2.13 -0.7%	$9.00 +323.5%	-10.8%	$135.32M	N/A	N/A	N/A
RLMD Relmada Therapeutics	2.3882 of 5 stars	$5.09 -2.0%	$12.00 +135.6%	+797.7%	$533.26M	N/A	N/A	10	Positive News Upcoming Earnings
PRME Prime Medicine	3.4222 of 5 stars	$2.93 -2.8%	$7.53 +157.5%	N/A	$526.51M	$4.63M	N/A	N/A	News Coverage Gap Up
NGNE Neurogene	3.1548 of 5 stars	$33.32 -3.7%	$84.83 +154.6%	+50.9%	$526.46M	$930K	N/A	90	News Coverage Positive News Upcoming Earnings
ARVN Arvinas	3.0739 of 5 stars	$8.12 -1.2%	$15.42 +89.9%	+8.6%	$523.39M	$89.40M	N/A	420	News Coverage Earnings Report Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HURA) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TuHURA Biosciences (HURA) Competitors

HURA vs. RLMD, PRME, NGNE, ARVN, and SLN

How does TuHURA Biosciences compare to Relmada Therapeutics?

Summary

How does TuHURA Biosciences compare to Prime Medicine?

Summary

How does TuHURA Biosciences compare to Neurogene?

Summary

How does TuHURA Biosciences compare to Arvinas?

Summary

How does TuHURA Biosciences compare to Silence Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HURA vs. The Competition

TuHURA Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TuHURA Biosciences (HURA) Competitors

HURA vs. RLMD, PRME, NGNE, ARVN, and SLN

How does TuHURA Biosciences compare to Relmada Therapeutics?

Which has more risk & volatility, HURA or RLMD?

Does the media prefer HURA or RLMD?

Which has preferable earnings & valuation, HURA or RLMD?

Do analysts rate HURA or RLMD?

Do insiders and institutionals believe in HURA or RLMD?

Is HURA or RLMD more profitable?

Summary

How does TuHURA Biosciences compare to Prime Medicine?

Do insiders and institutionals have more ownership in PRME or HURA?

Does the media refer more to PRME or HURA?

Which has preferable earnings and valuation, PRME or HURA?

Do analysts prefer PRME or HURA?

Is PRME or HURA more profitable?

Which has more risk and volatility, PRME or HURA?

Summary

How does TuHURA Biosciences compare to Neurogene?

Do insiders & institutionals believe in HURA or NGNE?

Is HURA or NGNE more profitable?

Which has higher earnings & valuation, HURA or NGNE?

Which has more risk and volatility, HURA or NGNE?

Does the media prefer HURA or NGNE?

Do analysts recommend HURA or NGNE?

Summary

How does TuHURA Biosciences compare to Arvinas?

Does the media favor ARVN or HURA?

Which has more risk and volatility, ARVN or HURA?

Is ARVN or HURA more profitable?

Which has stronger earnings and valuation, ARVN or HURA?

Do insiders and institutionals hold more shares of ARVN or HURA?

Do analysts prefer ARVN or HURA?

Summary

How does TuHURA Biosciences compare to Silence Therapeutics?

Do institutionals and insiders have more ownership in HURA or SLN?

Do analysts recommend HURA or SLN?

Which has more risk and volatility, HURA or SLN?

Which has preferable earnings & valuation, HURA or SLN?

Is HURA or SLN more profitable?

Does the media refer more to HURA or SLN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HURA vs. The Competition

TuHURA Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools